SASI-Mab Bio-tech

SASI-Mab is a biotechnology company focused on developing targeted monoclonal antibody therapies for aggressive and metastatic cancers. Spun out of the University of South Alabama Mitchell Cancer Institute, the company leverages research into cancer stem cell markers to create precision biologics. Their lead candidate targets the Surface Antigen of Stem-like cells (SASI), a protein associated with tumor initiation and resistance to standard therapies. SASI-Mab's primary focus is on high-unmet-need indications, including triple-negative breast cancer and pancreatic adenocarcinoma. The company aims to integrate its antibody candidates into combination regimens to improve long-term patient outcomes.